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Abstract
Quantitative evaluation of lung tumor angiogenesis using immunohistochemical techniques has been limited by dif-
ficulties in generating reproducible data. To analyze intrapulmonary tumor angiogenesis, we used high-resolution
micro–computed tomography (micro-CT) of lung tumors of mice inoculated with mouse Lewis lung carcinoma
(LLC1) or human adenocarcinoma (A549) cell lines. The lung vasculature was filled with the radiopaque silicone
rubber, Microfil, through the jugular vein (in vivo application) or pulmonary artery (ex vivo application). In addition,
human adenocarcinoma lung tumor–bearing mice treated site-specifically with humanized monoclonal antibody
(bevacizumab) against vascular endothelial growth factor. Quantitative analysis of lung tumor microvessels imaged
with micro-CT showed that more vessels (mainly small, <0.02 mm2) were filled using the in vivo (5.4%) compared
with the ex vivo (2.1%) method. Furthermore, bevacizumab-treated lung tumor–bearing mice showed significantly
reduced lung tumor volume and lung tumor angiogenesis compared with untreated mice as assessed by micro-CT.
Interestingly, microvascularization of mainly the smaller vessels (<0.02 mm2) was reduced after bevacizumab treat-
ment. This observation with micro-CT was nicely correlated with immunohistochemical measurement of micro-
vessels. Therefore, micro-CT is a novel method for investigating lung tumor angiogenesis, and this might be
considered as an additional complementary tool for precise quantification of angiogenesis.
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Introduction
Lung cancer affects a greater number of people worldwide than any
other cancer and is the leading cause of cancer death (∼28%) in both
men and women. The global incidence of this disease is rising by
∼0.5% per year, and the number of cancer deaths caused by lung
cancer expected to increase to 50% by 2020 [1]. Because lung cancer
patients are typically diagnosed at a late stage, prognosis for most pa-
tients remains poor, with a 5-year survival rate of less than 15%. The
current situation highlights the fact that lung cancer treatment requires
new approaches, and recent research has focused on molecular-targeted
therapies [2].
Angiogenesis, the process of new blood vessel formation, is funda-
mental for the growth and spread of solid tumors. Generally, tumors
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cannot grow beyond 2 mm in diameter without developing a vas-
cular supply [3]. Moreover, angiogenesis not only permits further
growth of the primary tumor but also provides a means for metastatic
dissemination. Molecular abnormalities such as alterations in the ex-
pression of vascular endothelial growth factor (VEGF), basic fibroblast
growth factor, platelet-derived growth factor, transforming growth
factor-β, granulocyte/monocyte colony-stimulating factor, angiostatin,
and endostatin are responsible for this pathologic angiogenesis process
[4,5]. Therefore, inhibition of specific molecules essential for the
tumor vascular development has become a key therapeutic antitumor
strategy. The most promising of these targets is the VEGF pathway,
targeted either by preventing VEGF binding to its receptor or in-
hibiting signaling downstream from the receptor. The first drug to
use this concept was bevacizumab (Avastin), a humanized antibody
against VEGF, which was approved for lung cancer treatment world-
wide in 2006/2007 [6,7].
Recent evidence suggests that angiogenesis in many solid tumors is
a major factor in predicting the aggressiveness of the disease and pa-
tient survival in different tumor types, including lung cancer [8–12].
Specifically, high vascularity at the periphery of lung tumors has been
correlated with tumor progression [13]. Tumor vascularization is usu-
ally quantified by determining microvessel density either histologi-
cally, by a visual count of blood vessels under high-magnification
light microscopy, or immunohistochemically, by staining for endo-
thelial antigens such as CD34, CD31 (PECAM), von Willebrand
factor (vWF), factor VIII–related antigen, and VEGF [14].
The methods mentioned are relatively subjective, not truly quanti-
tative, and two dimensional, and are thus not necessarily representative
of vascularity throughout the entire sample. A recent meta-analysis of
individual patient data from published and unpublished data sets did
not demonstrate a prognostic value for microvessel density analysis in
patients with nonmetastatic surgically treated non–small cell lung
cancer [15]. Similarly, further studies in which the three-dimensional
(3D) structure of tumor microvasculature was obtained mainly by
analyzing histologic serial sections, and filling the blood vessels with
an opaque substance also posed inherent problems, such as mis-
alignment, missing sections, and imperfect perfusion [16–19]. Despite
these difficulties, accurate quantification of tumor angiogenesis has
recently been shown to be of potential significance. In this regard,
dynamic contrast-enhanced computed tomography (CT), dynamic
contrast-enhanced magnetic resonance imaging, flat-panel volumetric-
CT (fpvCT), and micro–CT have emerged as promising technologies
that can overcome several of the challenges associated with the evalua-
tion of vascular networks [20,21]. Moreover, micro-CT offers the
unique advantage of imaging a representative sample volume at high
resolution (∼5- to 10-μm isotropic voxels) without physically sectioning
it and without limitations related to either the plane of the section,
superimposition, or distortions frequently observed with histology.
Furthermore, the 3D nature of the micro-CT data set allows calcula-
tions of vessel tortuosity, an index of angiogenesis. Indeed, this tech-
nique has been used to visualize the vasculature in intact isolated
rodent organs [22] and the myocardial, renal, and hepatic vasculature
[23–27] and trabecular bones [28] in surgical bone specimens. Al-
though this technique allows serial imaging of vessel number and mor-
phology in ex vivo specimens, which might be useful in the evaluation
of angiogenesis and treatment options, to date, it has not been evalu-
ated in detail in experimental models of lung cancer.
In parallel with the development of high-resolution imaging and
quantification of angiogenesis of lung tumors, a need has arisen for
the development of site-specific treatment strategies that are efficacious
without the unacceptable systemic adverse effects of conventional treat-
ments. Along these lines, we recently used a combination of micro-
scopic analysis of infused fluorescent microspheres and 3D images
obtained by micro-CT and fpvCT to show that the pulmonary arterial
system plays a predominant role in the blood supply of orthotopic lung
tumors in mice [29].
The purposes of our study were to (i) evaluate the feasibility of
micro-CT for the quantification of lung tumor angiogenesis, (ii) cor-
relate micro-CT data with histologic data, and (iii) quantify the anti-
angiogenic effect of site-specifically delivered bevacizumab in a mouse
model of lung cancer.
Materials and Methods
Cell Lines and Culture Conditions
Mouse Lewis lung carcinoma (LLC1) and human A549 lung adeno-
carcinoma cell lines were obtained from American Type Culture
Collection (Manassas, VA). LLC1 cells were maintained in RPMI-
1640 medium supplemented with 2% fetal bovine serum, penicillin
(100 U/ml), and streptomycin (0.1 mg/ml) at 37°C in a humidified
atmosphere containing 5% CO2. A549 cells were maintained in
Dulbecco’s modified Eagle’s medium/F-12 medium supplemented
with 10% fetal bovine serum, penicillin (100 U/ml), streptomycin
(0.1 mg/ml), 1% minimum essential medium vitamin solution,
2 mM glutamate, and 1% nonessential amino acids at 37°C in a
humidified atmosphere containing 5% CO2 (all reagents were from
Gibco, Germany).
Lung Tumor Xenograft Models
Female C57/BL6 (5-7 weeks old) and BALB/c nu/nu (7-8 weeks
old) mice were purchased from Charles Rivers, Sulzfeld, Germany,
kept under pathogen-free conditions, and handled in accordance
with the University of Giessen recommendations for experimenta-
tion. The lung tumor models was generated by intratracheal instilla-
tion of 1 × 106 LLC1 cells into C57/BL6 mice and 2 × 106 A549
cells into BALB/c nu/nu mice as described [29,30]. For all the experi-
ments (intratracheal instillation, treatment, and microfill injections),
mice were anesthetized by intraperitoneal injection of a mixture con-
taining ketamine (100 mg/ml; Ketavet; Pharmacia & Upjohn, Erlangen,
Germany) and xylazine (2%; Rompun; Bayer, Leverkusen, Germany).
Treatment of Lung Tumor–Bearing Mice
After detecting lung tumors with fpvCT 5 to 6 weeks after tumor
cell injection, human A549 adenocarcinoma tumor–bearing mice
were anesthetized and implanted with osmotic minipumps (Model
2002; Alzet Corp., Palo Alto, CA) for continuous drug administra-
tion according to the manufacturer’s instructions. Briefly, osmotic
minipumps were filled with distilled water (200 μl per pump) or anti-
VEGF antibody bevacizumab (Avastin; Roche, Welwyn Garden City,
UK; dose, 5 mg/200 μl per pump) and were incubated in isotonic
saline 24 hours at 37°C before implantation. In vitro testing showed
that the minipumps reached a steady pumping rate in 24 hours. The
pump was implanted intraperitoneally and connected to a jugular cathe-
ter that was introduced into the jugular vein under sterile conditions
from a small midline incision. The incision was closed in two layers with
polypropylene sutures [31]. These pumps (internal volume, 200 μl)
continuously delivered bevacizumab at a rate of 0.5 μl/h for 14 days.
To monitor the effects of bevacizumab on lung tumor growth, mice
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were scanned with fpvCT. At the end of the treatment protocol, mice
were anesthetized and injected with Microfil for micro-CT scannings.
Micro-CT
After confirming the presence of lung tumors in mice using fpvCT
[29,30] (data not shown), blood vessels were filled with a solidifying
silicone rubber blood pool contrast agent (Microfil; Flow Tech, Carver,
MA) to form a vascular cast for investigations using micro-CT. Under
visual control, ready-made nondiluted Microfil was manually perfused
using two different methods as described [29,32]. Briefly, mice were
infused with heparin and either (i) the lung vascular tree was com-
pletely filled by in vivo injection through the jugular vein or (ii) the
pulmonary arteries were filled by direct injection of Microfil into the
main pulmonary artery ex vivo. After perfusion and solidification of
the contrast medium, the lungs were removed and scanned with a
desktop micro-CTunit (Skyscan1072; Skyscan, Aartselaar, Belgium) as
described [29,32]. Samples were positioned on a computer-controlled
rotation stage and scanned 180° around the vertical axis in rotation
steps of 0.675° at 60 kV. Acquisition time for each view was 2.4 sec-
onds. Raw data were reconstructed with a modified Feldkamp cone-
beam reconstruction algorithm, resulting in 8-bit grayscale images
with 6- to 10-μm3 isotropic voxels. Image processing, tissue density
measurements, extraction of lung tumors, quantification of tumor
vascularization, and tree analysis on tumor vascularization were per-
formed with the Analyze 7.0 software package (Analyze; Biomedical
Imaging Resource, Mayo Foundation, Rochester, MN). After treat-
ment with bevacizumab in BALB/c nu/nu mice, lungs were moni-
tored with fpvCT, and lung vasculature was filled in vivo as above
for micro-CT investigation.
Immunohistochemistry
Lungs were harvested, and each lung lobe was embedded in par-
affin blocks and sectioned at 3 μm. A total of 50 to 80 serial sections
were made from each lung lobe tissue block. Sections were stained
with hematoxylin and eosin and were analyzed using a light micro-
scope (Leica Instruments, Nussloch, Germany) for the presence of
the tumor mass for correlation with the micro-CT images.
After deparaffinization of the lung tumor sections, endogenous per-
oxidases were blocked with 0.3% (v/v) H2O2 in methanol and then
blocked with 5% (v/v) bovine serum albumin in phosphate-buffered
saline, followed by incubation with rabbit polyclonal anti-vWF (dilu-
tion 1:800; Dako, Hamburg, Germany) and rabbit polyclonal anti–
proliferating cell nuclear antigen (PCNA, dilution 1:200; Santa Cruz
Biotechnology, Santa Cruz, CA). Sections were washed in phosphate-
buffered saline, and antibody binding was determined using an
ImmPRESS reagent kit (Vector Laboratories, Burlingame, CA). After
extensive washing, sections were stained with vector VIP and NovaRED
(Vector Laboratories) and counterstained with nuclear fast red and he-
matoxylin (Vector Laboratories). The immunohistologic staining for
vWF and PCNA was quantified in 10 different randomly chosen fields
of lung tumor sections by light microscopy at a magnification of 100×.
Results
Analysis of micro-CT Images
In vivo injection of Microfil through the jugular vein and ex vivo
injection of Microfil through the pulmonary artery both resulted in
fixation of the pulmonary vascular tree with preservation of both
microarchitecture and 3D interconnectivity of the entire lung (Fig-
ure 1). Both methods resulted in successful filling of the pulmonary
arteries down to the level of the alveolar capillaries and a clear visu-
alization of the pulmonary microcirculation to lung tissue and lung
tumors (Figure 1). The high-resolution 3D renderings of the vascular
tree micro-CT images of intrapulmonary tumors and their micro-
vascularization images were generated with 3D maximum intensity
projection (MIP) and 3D volume rendering technique (VRT). The
3D MIP images (Figure 1A) show the main anatomical lung features
such as tumor mass, pulmonary arteries, pulmonary veins, trachea,
mediasternum, and esophagus. The 3D VRT images (Figure 1B)
show large and microvessels in the lung and microvessels (pulmonary
arteries, pulmonary veins) distributed in the whole lung.
The micro-CT images were compared to the corresponding histo-
logic images—the criterion standard for morphologic analysis—and
the samples showed a high degree of agreement by visual assessment
for both in vivo and ex vivo vessel filling (Figure 1C ). Figure 1D
shows a clear correlation between the two imaging techniques, and
the anatomical structures of tumor masses, Microfil-filled vascula-
ture, pulmonary arteries, and bronchoalveolar structures are observed
in both the micro-CT and histology images.
Quantification of Lung Tumors and Lung Tumor Microvessels
After analyzing whole-lung images using ex vivo and in vivo vessel
filling methods, the tumor masses were selected and virtually extracted
from the lung images and tumor volume and tumor vessel volume
were measured (Figure 2A). Interestingly, in vivo–filled tumors had
more vessels perfused compared to ex vivo–filled tumors. With the
in vivo filling method, the tumor volume was 2.93 ± 0.83 mm3,
and the perfused tumor vessel volume was 0.16 ± 0.03 mm3, thus
implying a 5.4 ± 0.4% vessel volume contribution to the total tumor
volume (Figure 2B). The ex vivo filling method measured a 3.47 ±
1.00-mm3 lung tumor volume and a 0.08 ± 0.03-mm3 perfused tumor
vessel volume, thus implying a 2.2 ± 0.32% vessel volume contribu-
tion to the total tumor volume (Figure 2C). These results nicely cor-
related with tumor microvessel quantification.
More microvessels (0.001-0.01 mm2 in diameter) were filled in the
in vivo–filled tumors compared to the ex vivo–filled tumors (2039 vs
1214, respectively). Similar differences between in vivo and ex vivo fill-
ing were also found in microvessels ranging from 0.051 to 0.06 mm2
in diameter (27.4 vs 21.5, respectively), suggesting that more micro-
vessels were perfused with the in vivo vessel filling method compared
to the ex vivo filling method (Figure 3).
Quantitative Analysis of Angiogenesis with
Site-Specific Therapy
To quantify the potential antiangiogenic effect of bevacizumab,
after detecting lung tumors with fpvCT (data not shown), animals were
treated with bevacizumab, and contrast-enhanced 3D MIP images from
untreated and bevacizumab-treated mice were obtained after 14 days
of treatment. As anticipated, bevacizumab treatment reduced tumor
growth (Figure 4A). In addition, tumor angiogenesis in extracted tumors
was significantly reduced in bevacizumab-treated animals compared to
untreated animals (Figure 4B). Moreover, the mean survival rate in-
creased with bevacizumab therapy (data not shown).
Quantification of tumor angiogenesis demonstrated a significant
reduction of tumor size and tumor angiogenesis in the bevacizumab-
treated group compared to the untreated group (tumor volume, 0.76 ±
0.14 vs 4.12 ± 0.64; and vessel volume, 0.06 ± 0.01 vs 0.39 ± 0.06,
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respectively; Figure 3B). Importantly, the number of microvessels
(0.0005-0.0104 mm2 in diameter, 38,579 vs 18,781; 0.0905-
0.1004 mm2 in diameter, 187 vs 10, for untreated vs bevacizumab-
treated, respectively) was drastically reduced with bevacizumab treatment
(Figure 4C).
Tree analysis of tumor angiogenesis provided information on vessel
structures, branching angles, and segment cross-sectional vessel area
sizes. When the tree analysis or branching schematics was started at
the initial seed point (∼149 mm2), in the bevacizumab-treated group,
there were substantially less branching points at a smaller diameter
(<25 mm2) compared with the untreated group, confirming the anti-
angiogenesis effects of bevacizumab (Figure 5, A and B).
Histomorphologic Analysis
Hematoxylin and eosin images of lung tumors of bevacizumab-
treated mice showed smaller lung tumors and hemorrhage around
the tumor masses compared to tumors of untreated animals (Fig-
ure 6A). In addition, analysis of the proliferation and vascularization
of tumors derived from bevacizumab-treated and untreated tumor
tissues by staining vessels with anti-vWF and assessing cell prolif-
eration with immunohistochemical staining for the marker PCNA
(Figure 6A). Quantitative analysis indicated a lower tumor vascular den-
sity (Figure 6B) and lower number of proliferating cells in bevacizumab-
treated lung tumors (Figure 6C ). Tissue density measurement by
micro-CT of normal lung and lung tumor tissue in bevacizumab-
treated and untreated mice with and without Microfil revealed a
decrease in lung tumor tissue with contrast fluid in the treated
group compared to the untreated group (Figure 6D), indicating that
bevacizumab-treated tumor tissues were more prone to hemorrhage.
Discussion
The aim of this study was to assess the feasibility of micro-CT
imaging for the quantification of lung tumor angiogenesis in Lewis
lung carcinoma and adenocarcinoma mouse models. We found that
micro-CT provided a detailed visualization of the vascular system
of the mouse lung and lung tumors. Previous studies have described
the capability of micro-CT to detect changes in organ microvascula-
ture and its distribution pattern and connectivity [33,34]. However,
this technology has not yet been used to measure mouse intrapul-
monary tumors and their vascular content. When using micro-CT im-
aging for analysis of tumor vasculature [35], defining the binarization
threshold and the scanning resolution are important methodological as-
pects that must be considered; we chose a binarization threshold value
Figure 1.Micro-CT and histology of an entire murine lung after in vivo or ex vivo injection of Microfil. (A) Three-dimensional MIP images
of the entire lung after in vivo or ex vivo Microfil application. (B) Three-dimensional VRT images of the entire lung after in vivo or ex vivo
Microfil application. Representative micro-CT and hematoxylin and eosin–stained images clearly showed the course of anatomical struc-
tures. (C) Three-dimensional MIP images (in vivo or ex vivo Microfil application) reconstructed from micro-CT images and the
corresponding (D) histologic images (in vivo or ex vivo Microfil application). b indicates bronchus; es, esophagus; il, inflated lung;
m, mediasternum; pa, pulmonary arteries; pv, pulmonary veins; tm, tumor mass; tr, trachea.
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Figure 2. Quantitative volumetric measurements of extracted tumors and tumor angiogenesis after in vivo or ex vivo vessel filling. (A)
A section of a Microfil-injected lung lobe: grayscale image of an extracted tumor from a Microfil-injected lung, MIP image showing a
lung tumor, and a VRT image illustrating the tumor vasculature in a sequential order. Quantitative scatter graphs showing the percent-
age of filled vessels in tumors after in vivo (B) or ex vivo (C) Microfil application. tm indicates tumor mass; v, vessels (n= 16 tumors were
taken for this analysis from 12 mice).
Figure 3. Quantitative measurement of tumor angiogenesis after in vivo or ex vivo vessel filling: bar graph showing the detailed infor-
mation that vessels were in tumor by vessel area (mm2; n = 16 tumors were taken for this analysis from 12 mice).
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that captured the intricate details of tumor microvasculature with min-
imal overestimation of broader structures. Likewise, the voxel size (6-
10 μm3) used for the scan was also selected to image smaller vascular
structures [36].
In our study, although only vessels perfused with sufficient contrast
material could be visualized and quantified, by using tomographic
reconstruction algorithms, vessel images allowed complete stereoscopic
visualization of the 3D microarchitecture of the lung tumors. As to-
mography allows convenient extraction of appropriate sections from
3D images, micro-CTalso can be used to analyze and quantify distinct
regions of interest more accurately. Furthermore, Microfil-enhanced
micro-CT images (through ex vivo or in vivo filling methods) accurately
depicted large-, intermediate-, and small-diameter vessels in tumors,
agreed well with the corresponding histologic images (the criterion stan-
dard for tumor vessel visualization), and was useful in identifying the
origin of the vessels feeding the tumors. Interestingly, in vivo injection
of Microfil through the jugular vein filled small vessels (diameter,
0.001-0.01 mm2) of lung tumors more efficiently than the ex vivo in-
jection of Microfil through the pulmonary artery. Further, the in vivo–
filled vessels could be tracked over long distances to their origin, allow-
ing subsequent detection of approximately two-fold greater perfused
vascular content in tumors, indicating that this method is a good choice
for contrast-enhanced micro-CT for the detection of angiogenesis. The
difference observed in vessel filling using the two instillation methods
may be due to differences in vascular pressures. In support, the work of
Molthen et al. [37] has shown that this can have a significant effect on
vessel diameter and on the ability of the contrast to perfuse into small
vessels (capillary pressure).
Because of its ability to generate a comprehensive display of vas-
culature and vessel size-specific alterations, micro-CTmay be ideally
suited for quantification of tumor angiogenesis and assessment of
antitumor treatment effects. As our previous study demonstrated that
Figure 4. Measurements of tumor angiogenesis after site-specific therapy. (A) Three-dimensional surface rendering images of lung tu-
mors from untreated and bevacizumab-treated mice. Extracted tumors and tumor microvascularization are shown (yellow represents
tumor tissue area; red represents tumor vessel area). (B) Number of vessels measured with micro-CT after 14 days of bevacizumab
treatment (•) or without treatment (▴). (C) Bar graph showing the detailed information that vessels were in tumor by vessel area(mm2; n = 12 mice for each group; extracted tumors from each mouse = ∼5-6).
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Figure 5. Lung tumor vascular branching by tree analysis: 3D MIP images, 3D VRT images, and vessel branching micrographs acquired
from tree analysis of micro-CT of tumors from untreated (A) and bevacizumab-treated (B) mice. Colored circles in the branching schematics
show the vessel branch points in the tumor and the vessel area: blue circles, <25 mm2; green circles, 25 to 100 mm2; pink circles, 100 to
150 mm2 (n = 6 tumors were used for each group).
Figure 6. Histopathology of lung tumors that received bevacizumab therapy. (A) Histologic images of sections (3 μm) from untreated
and bevacizumab-treated lung tumor sections that were stained with hematoxylin and eosin (H&E; the black dashed lines indicate areas
of hemorrhage in the tumor), with anti-vWF (red arrows in A indicate vWF-positive vessels) and anti-PCNA (black arrows in A indicate
PCNA-positive cells), respectively. Quantification of vWF-positive tumor vessels (B) and PCNA-positive tumor cells (C) by counting posi-
tively stained cells in ten randomly selected microscopic fields in seven mice is given. (D) Lung and lung tumor tissue density with or
without Microfil were measured with micro-CT (60 areas were selected). Means ± SEM are shown. Scale bars, 40 μm.
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the pulmonary arterial system plays an important role in the blood
supply of LLC1 lung tumors [29], we implanted the A549 tumor–
bearing mice with osmotic minipumps (bevacizumab-filled) through
the jugular vein. This delivery mimics local delivery of antivascular
agents and can be used effectively alone or in combination with cyto-
toxic chemotherapy for site-specific drug delivery for lung cancer
treatment. As expected, continuous infusion of bevacizumab de-
creased lung tumor volume and tumor perfusion, with an added
survival advantage compared to the untreated group. Furthermore,
vessel volume and vessel area were also significantly decreased with
bevacizumab treatment.
Most interestingly, our new technique allowed us to measure vessel
area, and analysis of vascular tree suggested that bevacizumab treat-
ment substantially reduced the number of small immature tumor ves-
sels (<25 mm2) that contribute the most to tumor nutrition. However,
bevacizumab treatment had less influence on mature vessels in lung
tumors, only affecting vessel dilation. These results are in line with
previous studies indicating that antiangiogenic treatment has a rela-
tively greater effect on the small/immature vasculature compared to
other parts of the vasculature [38–40].
Micro-CT has several additional features compared with other
techniques for tumor vessel morphologic evaluation and measure-
ment of vessel content. Compared to histomorphometric procedures,
micro-CT provides the opportunity to study the 3D connectivity of
vessels and more convenient imaging of the entire organ and hence
can be an alternative for quantitative measurement of intrapulmonary
tumors and their vascular content in the Lewis lung carcinoma and
adenocarcinoma tumor–bearing mouse models. In addition, micro-
CT provides the ability to quantify the vascular parameters. Further-
more, in contrast to fpvCT, micro-CTallows the detection of immature
vessels, a potential site of antiangiogenic treatment [41].
The angiogenic switch is a key event in tumor progression to
a malignant, invasive, and ultimately metastasizing tumor, making
angiogenesis as one of the most promising targets for novel cancer
therapies. Because micro-CT, as shown in our study, can analyze
tumor vascular networks in a rigorous and quantitative manner,
micro-CT imaging can enhance our understanding of the impact
of tumor angiogenesis and opens the possibility for future monitor-
ing of lung cancer progression and treatment.
In conclusion, our study is the first to demonstrate micro-CT as
an ideal modality to visualize the architecture of the mouse lung and
lung tumor vasculature and, most importantly, to derive quantita-
tive information from these images in LLC1 and A549 lung tumor
mouse models.
An important factor in the clinical application of antiangiogenic
therapy is early assessment of the therapeutic effects to predict therapy
response and to allow for individualized treatment to improve out-
comes. Thus, monitoring of the effects of angiogenic inhibitors on
tumor vasculature has become the focus of both basic and clinical can-
cer researches. In this context, this study emphasizes the potential im-
plications of vascular imaging and further expansion of new in vivo
imaging systems for clinical cancer diagnosis and therapeutic planning.
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